Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brensocatib - Insmed

Next Previous
X
Search
Drug Profile

Brensocatib - Insmed

Alternative Names: AZD 7986; INS-1007

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Insmed
  • Class Amides; Anti-inflammatories; Antibronchitics; Benzoxazoles; Nitriles; Oxazepines; Skin disorder therapies; Small molecules
  • Mechanism of Action Dipeptidyl peptidase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bronchiectasis
  • Phase II Rhinosinusitis
  • Phase I Hidradenitis suppurativa
  • Discontinued Chronic obstructive pulmonary disease; COVID 2019 infections; Cystic fibrosis; Granulomatosis with polyangiitis

Most Recent Events

  • 15 Jul 2024 Discontinued - Phase-II for Granulomatosis with polyangiitis (In the elderly, In adults) in France (PO) prior to July 2024 (Insmed pipeline, July 2024)
  • 12 Jun 2024 Discontinued - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (PO) (AstraZeneca pipeline, June 2024)
  • 28 May 2024 Insmed announces intention to submit NDA to US FDA for Bronchiectasis (Non-cystic fibrosis-related) in 4Q of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top